SCHEMBL4965608

SCHEMBL4965608

CCCCC(O)NCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 4/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
FAAH O00519 4/20 0.36
DPP7 Q9UHL4 1/20 0.34
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
SPHK1 Q9NYA1 1/20 0.33
GMNN O75496 1/20 0.33
POLB P06746 1/20 0.33
THPO P40225 1/20 0.33
MTOR P42345 1/20 0.33
BLM P54132 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9801229 0.93 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801760 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801617 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801090 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801644 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801160 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801038 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801552 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL9801084 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10
SCHEMBL28429481 0.91 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1459765-B1 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2008-08-20 EP disclosed
US-7157594-B2 6-Fluorobicyclo[3.1.0]hexane derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20050119345-A1 6-Fluorobicyclo[3.1.0]hexane derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-06-02 US disclosed
EP-1459765-A1 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2004-09-22 EP disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119345-A1 6-Fluorobicyclo[3.1.0]hexane derivatives GRM1, GRM2, GRM6 ALDH1A1 531/4885SMN1; SMN2 4123/4885LMNA 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.